| scholarly article | Q13442814 |
| P356 | DOI | 10.1189/JLB.0103010 |
| P698 | PubMed publication ID | 12885935 |
| P50 | author | Dmitry I. Gabrilovich | Q16729133 |
| Sergei Kusmartsev | Q73284799 | ||
| P433 | issue | 2 | |
| P921 | main subject | cell differentiation | Q210861 |
| reactive oxygen species | Q424361 | ||
| P304 | page(s) | 186-196 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Journal of Leukocyte Biology | Q1524048 |
| P1476 | title | Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species | |
| P478 | volume | 74 |
| Q30544892 | A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects |
| Q36988746 | Advancements in immune tolerance |
| Q35062106 | All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients |
| Q36260673 | Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer |
| Q33733198 | Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. |
| Q53694854 | Arginase-1 expression in myeloid cells regulates S. aureus planktonic but not biofilm infection. |
| Q27011356 | Beyond oxidative stress: an immunologist's guide to reactive oxygen species |
| Q35592362 | Bone-immune cell crosstalk: bone diseases. |
| Q90290824 | Cancer-Derived Exosomes as Effectors of Key Inflammation-Related Players |
| Q37066900 | Cross talk between ceramide and redox signaling: implications for endothelial dysfunction and renal disease |
| Q34353081 | DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth |
| Q89723185 | Decreased plasma riboflavin is associated with poor prognosis, invasion, and metastasis in esophageal squamous cell carcinoma |
| Q59126825 | Dietary Supplementation of Selenoneine-Containing Tuna Dark Muscle Extract Effectively Reduces Pathology of Experimental Colorectal Cancers in Mice |
| Q35227738 | Dopamine inhibits the function of Gr-1+CD115+ myeloid-derived suppressor cells through D1-like receptors and enhances anti-tumor immunity |
| Q37246466 | Down-regulation of PLCγ2-β-catenin pathway promotes activation and expansion of myeloid-derived suppressor cells in cancer. |
| Q37699662 | EPCs and pathological angiogenesis: when good cells go bad. |
| Q36597391 | Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer |
| Q58129606 | Embelin impairs the accumulation and activation of MDSCs in colitis-associated tumorigenesis |
| Q35841859 | Enhancement by other compounds of the anti-cancer activity of vitamin D(3) and its analogs. |
| Q37999967 | From genes to drugs: targeted strategies for melanoma |
| Q51360802 | Gender bias in skin cancer: role of catalase revealed. |
| Q34243443 | HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment |
| Q36621785 | High immune response rates and decreased frequencies of regulatory T cells in metastatic renal cell carcinoma patients after tumor cell vaccination |
| Q28392943 | Histamine promotes the development of monocyte-derived dendritic cells and reduces tumor growth by targeting the myeloid NADPH oxidase |
| Q35757368 | IL-10 contributes to the suppressive function of tumour-associated myeloid cells and enhances myeloid cell accumulation in tumours. |
| Q35642044 | Immune microenvironments in solid tumors: new targets for therapy |
| Q27005871 | Immune regulation of bone metastasis |
| Q33584851 | Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer |
| Q55360009 | Immunomodulatory Function of Myeloid-Derived Suppressor Cells during B Cell-Mediated Immune Responses. |
| Q58561592 | Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression |
| Q38767735 | Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. |
| Q29636247 | Immunosuppressive strategies that are mediated by tumor cells |
| Q37162897 | In Vitro and In Vivo Anticancer Effects of Sterol Fraction from Red Algae Porphyra dentata. |
| Q50709001 | In Vivo Mobilization and Functional Characterization of Nonhuman Primate Monocytic Myeloid-Derived Suppressor Cells. |
| Q37822291 | In vivo imaging of immune cell trafficking in cancer |
| Q42728755 | In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site |
| Q36108095 | Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy |
| Q24641894 | Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein |
| Q35101890 | Lipid raft redox signaling: molecular mechanisms in health and disease |
| Q33705930 | Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. |
| Q33707270 | Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells |
| Q35968465 | Mechanisms and functional significance of tumour-induced dendritic-cell defects |
| Q39458697 | Mechanisms regulating immune surveillance of cellular stress in cancer. |
| Q83952143 | Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow |
| Q37035365 | Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression |
| Q36229458 | MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis |
| Q38160782 | Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly |
| Q89976160 | Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer |
| Q37778697 | Myeloid-Derived Suppressor Cells in Human Cancer |
| Q27000087 | Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship |
| Q28131637 | Myeloid-derived suppressor cells as regulators of the immune system |
| Q37732211 | Myeloid-derived suppressor cells contribute to Staphylococcus aureus orthopedic biofilm infection |
| Q36018144 | Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response |
| Q37727645 | Myeloid-derived suppressor cells in gliomas |
| Q84564794 | Myeloid-derived suppressor cells in inflammation: uncovering cell subsets with enhanced immunosuppressive functions |
| Q36607445 | Myeloid-derived suppressor cells in murine retrovirus-induced AIDS inhibit T- and B-cell responses in vitro that are used to define the immunodeficiency |
| Q33786718 | Myeloid-derived suppressor cells in sepsis |
| Q34903354 | Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice |
| Q36896764 | Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer |
| Q24641811 | Myeloid-derived suppressor cells: linking inflammation and cancer |
| Q30411008 | Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? |
| Q35915642 | NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment |
| Q26773135 | Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity |
| Q33739465 | Paradoxical myeloid-derived suppressor cell reduction in the bone marrow of SIV chronically infected macaques. |
| Q36156031 | Phenotypic, morphological, and functional heterogeneity of splenic immature myeloid cells in the host response to tularemia |
| Q24658240 | Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells |
| Q26740114 | Reactive Oxygen Species Regulate T Cell Immune Response in the Tumor Microenvironment |
| Q58698002 | Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression |
| Q51748168 | Redox control of cancer cell destruction. |
| Q34314210 | Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway |
| Q35578604 | Regulation of dendritic-cell differentiation by bone marrow stroma via different Notch ligands |
| Q37982182 | Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells |
| Q36384598 | Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function |
| Q90396294 | Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance |
| Q36208862 | Role of immature myeloid cells in mechanisms of immune evasion in cancer |
| Q64377294 | Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection |
| Q37553132 | Stat3 and C/EBPβ synergize to induce miR-21 and miR-181b expression during sepsis |
| Q29614297 | Subsets of myeloid-derived suppressor cells in tumor-bearing mice |
| Q36109953 | Suppression of dendritic cell maturation and T cell proliferation by synovial fluid myeloid cells from mice with autoimmune arthritis. |
| Q39399239 | Taming the immune system through transfusion in oncology patients |
| Q37642591 | The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells |
| Q89924022 | The DNA methyltransferase inhibitor, guadecitabine, targets tumor-induced myelopoiesis and recovers T cell activity to slow tumor growth in combination with adoptive immunotherapy in a mouse model of breast cancer |
| Q94545420 | The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment |
| Q36945956 | The IL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis |
| Q33660069 | The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. |
| Q37770271 | Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for regulation and therapy of liver auto- and alloimmunity |
| Q35285811 | Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain |
| Q35795835 | Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design |
| Q34312635 | Tumor-associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells |
| Q50424573 | Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFα and NO-dependent mechanism, promoting a tumor-supportive environment |
| Q35981563 | Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release |
| Q92502928 | Tumour-associated neutrophils in patients with cancer |
| Q35722475 | UV light B-mediated inhibition of skin catalase activity promotes Gr-1+ CD11b+ myeloid cell expansion. |
| Q35174209 | Uncaria tomentosa for Reducing Side Effects Caused by Chemotherapy in CRC Patients: Clinical Trial |
Search more.